Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NRL005
MIFTS: 63

Neurilemmoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Neurilemmoma

About this section

MalaCards integrated aliases for Neurilemmoma:

Name: Neurilemmoma 12 53 59 44 15 73
Schwannoma 12 53 29 55 6
Benign Schwannoma 53 59 73
Peripheral Fibroblastoma 53 59
Neurilemoma 53 59
Psammomatous Schwannoma 12
Neurolemmoma 53

Characteristics:

Orphanet epidemiological data:

59
benign schwannoma
Prevalence: 1-9/100000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3192
MeSH 44 D009442
NCIt 50 C3269
Orphanet 59 ORPHA252164
UMLS via Orphanet 74 C0027809 C0854906
Sources

Summaries for Neurilemmoma

About this section
NIH Rare Diseases : 53 A schwannoma is a tumor of the peripheral nervous system or nerve root. A schwannoma develops from cells called Schwann cells, a type of cell that wraps itself around peripheral nerves and provides protection and support. Schwannomas are almost always benign (not cancerous), but rarely, may become cancerous (a malignant schwannoma). Symptoms of a schwannoma may be vague and will vary depending on its location and size, but may include a lump or bump that can be seen or felt, pain, muscle weakness, tingling, numbness, hearing problems, and/or facial paralysis. Sometimes schwannomas do not cause any symptoms. Schwannomas usually develop in otherwise healthy people for unknown reasons. In some cases, a schwannoma is caused by a genetic disorder such as neurofibromatosis 2 (NF2), schwannomatosis, or Carney complex. People with these genetic disorders usually have more than one schwannoma. Schwannomas may be diagnosed using imaging studies. A biopsy may confirm the diagnosis. Treatment of benign schwannomas may involve surgery to remove the tumor. Treatment of malignant schwannomas may include both surgery and radiation therapy.

MalaCards based summary : Neurilemmoma, also known as schwannoma, is related to schwannomatosis 1 and neurilemmomatosis. An important gene associated with Neurilemmoma is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are ERK Signaling and Cytoskeletal Signaling. The drugs Anti-Bacterial Agents and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, bone and liver, and related phenotypes are hearing abnormality and abnormality of the breast

Wikipedia : 76 A schwannoma is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce... more...

Sources

Related Diseases for Neurilemmoma

About this section

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 schwannomatosis 1 33.1 NF2 SMARCB1
2 neurilemmomatosis 32.5 NF1 NF2 PRKAR1A SMARCB1
3 cellular schwannoma 31.4 NF1 NF2 NGFR S100B SOX10
4 plexiform schwannoma 30.8 ENO2 GFAP KIT NF1 NF2 NGFR
5 pleomorphic adenoma 29.3 GFAP S100B VIM
6 leiomyoma 29.3 DES KIT VIM
7 oligodendroglioma 29.3 ENO2 GFAP PDGFRA SOX10
8 neurofibroma 29.2 KIT NF1 NF2 PDGFRA S100B SOX10
9 neuroma 29.1 ENO2 GFAP NF1 NF2 S100B SMARCB1
10 malignant peripheral nerve sheath tumor 28.8 KIT NF1 NF2 PDGFRA S100B SMARCB1
11 leiomyosarcoma 27.2 DES ENO2 KIT PDGFRA S100B VIM
12 mediastinal neurilemmoma 11.9
13 sympathetic neurilemmoma 11.9
14 melanotic neurilemmoma 11.9
15 neurilemmoma of the fifth cranial nerve 11.9
16 macrocystic neurilemmoma 11.8
17 mediastinal melanocytic neurilemmoma 11.8
18 neurilemmoma of the pleura 11.8
19 benign dermal neurilemmoma 11.8
20 benign mediastinal psammomatous neurilemmoma 11.8
21 benign mediastinal neurilemmoma 11.8
22 acoustic neuroma 11.2
23 monosomy 22 11.0 NF2 SMARCB1
24 neurofibromatosis, familial spinal 10.9 NF1 NF2
25 gliofibroma 10.9 GFAP NF1
26 cerebral convexity meningioma 10.9 GFAP NF2
27 large cell carcinoma with rhabdoid phenotype 10.9 ENO2 SMARCB1
28 deep leiomyoma 10.9 GFAP KIT
29 intraventricular meningioma 10.9 GFAP NF2
30 lung meningioma 10.8 ENO2 NF2
31 cornea cancer 10.8 GFAP NF2
32 meningothelial meningioma 10.8 ENO2 NF2
33 schwannoma of jugular foramen 10.8
34 mixed type thymoma 10.8 KIT S100B
35 gemistocytic astrocytoma 10.8 GFAP S100B
36 cutaneous ganglioneuroma 10.8 ENO2 KIT
37 duodenal somatostatinoma 10.8 ENO2 NF1
38 nodular medulloblastoma 10.8 GFAP SMARCB1
39 neurofibrosarcoma 10.8 NF1 NF2
40 kidney rhabdoid cancer 10.8 ENO2 SMARCB1
41 middle cerebral artery infarction 10.7 ENO2 S100B
42 aggressive digital papillary adenocarcinoma 10.7 KIT S100B
43 spinal cancer 10.7 GFAP NF2
44 cerebellar medulloblastoma 10.7 ENO2 GFAP
45 subependymal glioma 10.7 ENO2 GFAP
46 cerebellopontine angle tumor 10.7 GFAP NF2 SMARCB1
47 cerebral neuroblastoma 10.6 ENO2 GFAP
48 autosomal genetic disease 10.6 NF1 NF2 PRKAR1A
49 spinal cord ependymoma 10.6 GFAP NF1 NF2
50 extraosseous chondrosarcoma 10.6 ENO2 SMARCB1

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma
Sources

Symptoms & Phenotypes for Neurilemmoma

About this section

Human phenotypes related to Neurilemmoma:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hearing abnormality 59 32 frequent (33%) Frequent (79-30%) HP:0000364
2 abnormality of the breast 59 32 occasional (7.5%) Occasional (29-5%) HP:0000769
3 abnormality of the adrenal glands 59 32 occasional (7.5%) Occasional (29-5%) HP:0000834
4 abnormality of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0001392
5 abnormality of the larynx 59 32 occasional (7.5%) Occasional (29-5%) HP:0001600
6 morphological abnormality of the central nervous system 59 32 occasional (7.5%) Occasional (29-5%) HP:0002011
7 abnormality of esophagus morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0002031
8 vertigo 59 32 frequent (33%) Frequent (79-30%) HP:0002321
9 acute episodes of neuropathic symptoms 59 32 occasional (7.5%) Occasional (29-5%) HP:0003489
10 vestibular schwannoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0009588
11 peripheral schwannoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0009593
12 abnormality of the temporal bone 59 32 hallmark (90%) Very frequent (99-80%) HP:0009911
13 facial palsy 59 32 frequent (33%) Frequent (79-30%) HP:0010628
14 abnormality of the twelfth cranial nerve 59 32 occasional (7.5%) Occasional (29-5%) HP:0010826
15 abnormality of peripheral nervous system electrophysiology 59 32 hallmark (90%) Very frequent (99-80%) HP:0030177
16 allodynia 59 32 frequent (33%) Frequent (79-30%) HP:0012533
17 scleral schwannoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0100011
18 nasal polyposis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100582
19 intestinal polyposis 59 32 occasional (7.5%) Occasional (29-5%) HP:0200008
20 abnormality of parotid gland 59 Occasional (29-5%)
21 abnormality of the cranial nerves 59 Very frequent (99-80%)
22 abnormality of the fibula 59 Occasional (29-5%)
23 pain 59 Occasional (29-5%)
24 schwannoma 59 Very frequent (99-80%)
25 neurofibrosarcoma 59 Excluded (0%)
26 abnormal parotid gland morphology 32 occasional (7.5%) HP:0000197
27 abnormality of fibula morphology 32 occasional (7.5%) HP:0002991

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.45 PDGFRA
2 Decreased viability GR00221-A-1 10.45 NF1 SMARCB1 PDGFRA PRKAR1A KIT
3 Decreased viability GR00221-A-2 10.45 PRKAR1A NF1 SMARCB1
4 Decreased viability GR00221-A-3 10.45 PRKAR1A NF2 SMARCB1 PDGFRA
5 Decreased viability GR00221-A-4 10.45 PRKAR1A NF1 PDGFRA
6 Decreased viability GR00301-A 10.45 KIT
7 Decreased viability GR00381-A-1 10.45 SMARCB1
8 Decreased viability GR00402-S-2 10.45 NF1 SMARCB1 NF2 PDGFRA KIT PRKAR1A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 S100B SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 SOX10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 SMARCB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.9 SOX10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 SMARCB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 VIM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.9 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.9 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.9 SMARCB1 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 SOX10 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.9 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.9 SMARCB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.9 KIT VIM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 SOX10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 SOX10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.9 S100B VIM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 SOX10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.9 SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 SOX10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.9 SMARCB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.9 S100B SMARCB1 KIT SOX10 VIM
36 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.9 KIT
37 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.9 KIT
38 Increased proliferation GR00094-A 8.96 NF2 SMARCB1

MGI Mouse Phenotypes related to Neurilemmoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 GFAP NF1 KIT DES ENO2 PRKAR1A
2 cellular MP:0005384 10.3 ENO2 GFAP NF1 DES KIT NGFR
3 homeostasis/metabolism MP:0005376 10.27 GFAP NF1 DES KIT NGFR NF2
4 growth/size/body region MP:0005378 10.25 ENO2 KIT EZR GFAP NF1 NGFR
5 cardiovascular system MP:0005385 10.22 KIT GFAP DES NGFR NF1 PDGFRA
6 mortality/aging MP:0010768 10.21 KIT EZR GFAP NF1 DES NGFR
7 digestive/alimentary MP:0005381 10.19 EZR GFAP NF1 KIT NGFR PRKAR1A
8 immune system MP:0005387 10.18 KIT EZR GFAP NGFR NF1 NF2
9 embryo MP:0005380 10.13 KIT NF1 NF2 PDGFRA SMARCB1 PRKAR1A
10 craniofacial MP:0005382 10.09 ENO2 KIT NF1 NGFR NF2 PDGFRA
11 integument MP:0010771 10.06 KIT NGFR NF1 NF2 PDGFRA PRKAR1A
12 muscle MP:0005369 10.06 GFAP NF1 DES KIT NGFR PDGFRA
13 nervous system MP:0003631 10.02 ENO2 KIT GFAP PDGFRA NGFR NF1
14 neoplasm MP:0002006 9.91 NF1 KIT NF2 PDGFRA PRKAR1A SOX10
15 normal MP:0002873 9.91 MSN GFAP NF1 KIT NGFR PDGFRA
16 respiratory system MP:0005388 9.61 ENO2 NF1 KIT PRKAR1A PDGFRA NF2
17 pigmentation MP:0001186 9.55 KIT PDGFRA NF1 PRKAR1A SOX10
18 vision/eye MP:0005391 9.23 KIT GFAP NF1 NGFR NF2 SMARCB1
Sources

Drugs & Therapeutics for Neurilemmoma

About this section

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
2 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
3 Gentamicins Phase 4,Not Applicable
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
8
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
9
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
10
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
11 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
12 Antiemetics Phase 3
13 Anti-Inflammatory Agents Phase 3,Phase 2
14 Antineoplastic Agents, Hormonal Phase 3,Not Applicable
15 Autonomic Agents Phase 3
16 Gastrointestinal Agents Phase 3,Not Applicable
17 glucocorticoids Phase 3
18 Hormone Antagonists Phase 3
19 Hormones Phase 3
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
21 Methylprednisolone acetate Phase 3
22 Methylprednisolone Hemisuccinate Phase 3
23 Neuroprotective Agents Phase 3
24 Peripheral Nervous System Agents Phase 3,Phase 2
25 Prednisolone acetate Phase 3
26 Prednisolone hemisuccinate Phase 3
27 Prednisolone phosphate Phase 3
28 Protective Agents Phase 3,Phase 2
29 Alkylating Agents Phase 3,Phase 2,Phase 1
30 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
32
Isophosphamide mustard Phase 3,Phase 2 0
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
34 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
35
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
36
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
39
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
41
Etoposide Approved Phase 2 33419-42-0 36462
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
44
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
45
Pembrolizumab Approved Phase 2 1374853-91-4
46
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
47
nivolumab Approved Phase 2 946414-94-4
48
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
49
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
50
Adenosine Approved, Investigational Phase 2 58-61-7 60961

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery Completed NCT00438087 Phase 3 methylprednisolone
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
7 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
8 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
9 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
10 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
12 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
13 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
14 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
15 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
16 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
17 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
18 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
19 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
20 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
21 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
22 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
23 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
24 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
25 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
26 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
27 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
28 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
29 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
30 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
31 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
32 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
33 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
34 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
35 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
36 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
37 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
38 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
39 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
40 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
41 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
42 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
43 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
44 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
45 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Vistusertib
46 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2 PTC299
47 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
48 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
49 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
50 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Sources

Genetic Tests for Neurilemmoma

About this section

Genetic tests related to Neurilemmoma:

# Genetic test Affiliating Genes
1 Schwannoma 29
Sources

Anatomical Context for Neurilemmoma

About this section

MalaCards organs/tissues related to Neurilemmoma:

41
Tongue, Bone, Liver, Brain, Thyroid, Adrenal Gland, Tonsil
Sources

Publications for Neurilemmoma

About this section

Articles related to Neurilemmoma:

(show top 50) (show all 547)
# Title Authors Year
1
Benign diaphragmatic neurilemmoma mimicking a left adrenal cyst. ( 29484235 )
2018
2
A Rare Case of Primary Intrapulmonary Neurilemmoma Diagnosed in a 43-Year-Old Asymptomatic Man with a Well-defined Intrapulmonary Mass. ( 29441326 )
2018
3
Surgical management of a large neurilemmoma-like leiomyoma of the uterine cervix mimicking a retroperitoneal tumor. ( 28702500 )
2017
4
Neurilemmoma of Maxillary Alveolus: A Rare Case Report and Review of Literature. ( 29284981 )
2017
5
Experience of operative treatment in 27 patients with intraspinal neurilemmoma. ( 29085485 )
2017
6
Spindle cell type malignant peripheral nerve sheath tumor arising in benign schwannoma with multiple intraosseous spinal metastasis: A case report. ( 28505957 )
2017
7
Intraoral neurilemmoma of mental nerve mimicking as traumatic fibroma: An unusual presentation - A case report and literature review. ( 28479699 )
2017
8
Laparoscopic resection of retroperitoneal benign neurilemmoma. ( 28289669 )
2017
9
Erratum: Affiliation and corresponding author correction: Laparoscopic resection of retroperitoneal benign neurilemmoma. ( 28480189 )
2017
10
Neurilemmoma of the Vagus Nerve in the Poststyloid Parapharyngeal Space. ( 26894190 )
2016
11
Intraventricular Neurilemmoma (Schwannoma): Shall GFAP Immunostaining Be Regarded as a Histogenetical Tag or as a Mere Histomimetical Trait? ( 27446622 )
2016
12
Neurilemmoma Of External Ear, Confirmed By Immunohistochemistry-A Telepathological Communication Between Cyprus And India. ( 28828767 )
2016
13
Laparoscopic resection of benign schwannoma in the hepatoduodenal ligament: A case report and review of the literature. ( 27123115 )
2016
14
Recurrent Ancient Intraosseous Neurilemmoma of Maxilla: A Rare Case Report. ( 27499782 )
2016
15
Neurilemmoma in the floor of the mouth: a case report. ( 26904498 )
2016
16
Schwannoma (Neurilemmoma) on the Base of the Tongue: A Rare Clinical Case. ( 27018477 )
2016
17
Benign schwannoma of the maxillary antrum. ( 27095911 )
2016
18
Cervical vagus nerve neurilemmoma mimicking parathyroid adenoma. ( 27562903 )
2016
19
Neurilemmoma of Deep Peroneal Nerve Sensory Branch : Thermographic Findings with Compression Test. ( 26539275 )
2015
20
Surgical outcome of spinal neurilemmoma: two case reports. ( 25654395 )
2015
21
Neurilemmoma of Retromolar Region in the Oral Cavity. ( 26221545 )
2015
22
Retroperitoneal schwannomas: advantages of laparoscopic resection. Review of the literature and case presentation of a large paracaval benign schwannoma (with video). ( 25598061 )
2015
23
Vaginal Neurilemmoma: Case Report with Brief Review. ( 27217689 )
2015
24
Thoracic Neurilemmoma Presenting With Spinal Nerve Involvement in Promyelocytic Leukemia. ( 25950139 )
2015
25
Primary Neurilemmoma of the Thyroid Gland Clinically Mimicking Malignant Thyroid Nodule. ( 26498011 )
2015
26
Benign paravertebral ancient neurilemmoma in a young adult: a rare occurrence. ( 25738029 )
2015
27
Intestinal neurilemmoma. ( 24157416 )
2014
28
Benign schwannoma masquerading as a malignant metastatic lesion in a patient with renal cell carcinoma. ( 25276269 )
2014
29
Neurilemmoma of median nerve. ( 25983466 )
2014
30
Primary intraparotid peripheral nerve sheath tumour with characteristics of benign schwannoma in a horse. ( 24529508 )
2014
31
Intraosseous neurilemmoma of the proximal ulna. ( 25460435 )
2014
32
Penile neurilemmoma: Utility of fine-needle aspiration cytology in diagnosis of a rare entity. ( 25538392 )
2014
33
Neurilemmoma of lateral nasal wall. ( 25179720 )
2014
34
Benign schwannoma in supraclavicular region: a false-positive lymph node recurrence of breast cancer suspected by PET scan. ( 24744055 )
2014
35
Benign Schwannoma Mimicking Metastatic Lesion on F-18 FDG PET/CT in Differentiated Thyroid Cancer. ( 24900096 )
2013
36
Maxillary neurilemmoma-Rarest of the rare tumour: Report of 2 cases. ( 24129122 )
2013
37
Retroperitoneoscopic resection of a lower posterior mediastinal benign schwannoma using a transdiaphragmatic approach. ( 23652068 )
2013
38
Human pulmonary dirofilariasis coexisting with intercostal neurilemmoma: a case report and literature review. ( 24080016 )
2013
39
Lateral cervical approach combined with posterior thoracotomy for the treatment of giant neurilemmoma of the chest involving the neck. ( 22884113 )
2013
40
Elastographic and contrast-enhanced ultrasound features of a benign schwannoma of the common fibular nerve. ( 24432165 )
2013
41
A case of benign schwannoma of the ascending colon treated with laparoscopic-assisted wedge resection. ( 24229016 )
2013
42
Neurilemmoma Showing a Unique Growth Pattern in the Lateral Chest Wall: Both Inside and Outside the Thoracic Cavity. ( 23445787 )
2013
43
Laparoscopic phrenectomy for a diaphragmatic neurilemmoma. ( 24250705 )
2013
44
Recurrent benign schwannoma of the scalp: Case report. ( 23123417 )
2013
45
Rare retro-orbital intraconal occurrence of benign schwannoma - a case report. ( 24551692 )
2013
46
Ancient neurilemmoma: A rare oral tumor. ( 24574671 )
2013
47
A case of giant, benign schwannoma associated with total lung collapse by bloody effusion. ( 24023560 )
2013
48
Value of ultrasonography in neurilemmoma diagnosis: the role of round shape morphology. ( 22957323 )
2012
49
Rectal schwannoma (neurilemmoma). ( 22369805 )
2012
50
Giant neurilemmoma of the vagus nerve: a case report and review of literature. ( 23936960 )
2012
Sources

Variations for Neurilemmoma

About this section

ClinVar genetic disease variations for Neurilemmoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SMARCB1 NM_003073.4(SMARCB1): c.*82C> T single nucleotide variant Pathogenic rs878854600 GRCh38 Chromosome 22, 23834262: 23834262
2 SMARCB1 NM_003073.4(SMARCB1): c.*82C> T single nucleotide variant Pathogenic rs878854600 GRCh37 Chromosome 22, 24176449: 24176449

Copy number variations for Neurilemmoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplific ation SMARCB1 Schwannoma
Sources

Expression for Neurilemmoma

About this section
Search GEO for disease gene expression data for Neurilemmoma.
Sources

Pathways for Neurilemmoma

About this section

Pathways related to Neurilemmoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.36 DES EZR GFAP KIT MSN NF1
2
Cytoskeletal Signaling 4
12.21 DES EZR MSN NF2 VIM
3
Neuroscience 4
12.03 ENO2 GFAP NF1 NF2 NGFR PRKAR1A
4
Spinal Cord Injury 1
11.69 GFAP NGFR VIM
5
Glioblastoma Multiforme 64
11.63 NF1 NF2 PDGFRA
6
Cytoskeleton remodeling Neurofilaments 22
Show member pathways
 11.59 DES GFAP NES VIM
7
Melanocyte Development and Pigmentation 64
11.16 KIT PRKAR1A SOX10
8
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11 GFAP NES PDGFRA S100B SOX10 VIM
Sources

GO Terms for Neurilemmoma

About this section

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 ruffle GO:0001726 9.67 EZR NF2 S100B
2 apical part of cell GO:0045177 9.65 EZR MSN NF2
3 cell body GO:0044297 9.61 EZR GFAP NF2
4 intermediate filament GO:0005882 9.56 DES GFAP NES VIM
5 filopodium GO:0030175 9.54 EZR MSN NF2
6 uropod GO:0001931 9.51 EZR MSN
7 microvillus GO:0005902 9.5 EZR MSN PDGFRA
8 cytoplasm GO:0005737 9.47 DES ENO2 EZR GFAP KIT MSN
9 invadopodium GO:0071437 9.46 EZR MSN
10 astrocyte projection GO:0097449 9.4 EZR GFAP
11 intermediate filament cytoskeleton GO:0045111 9.33 DES GFAP NES
12 myelin sheath GO:0043209 9.26 ENO2 EZR GFAP MSN

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.83 KIT NF1 NF2 NGFR
2 negative regulation of protein kinase activity GO:0006469 9.75 NF1 NF2 PRKAR1A
3 positive regulation of gene expression GO:0010628 9.72 EZR KIT MSN SOX10 VIM
4 negative regulation of neuron projection development GO:0010977 9.61 GFAP NGFR VIM
5 negative regulation of cell-matrix adhesion GO:0001953 9.6 NF1 NF2
6 adrenal gland development GO:0030325 9.59 NF1 PDGFRA
7 astrocyte development GO:0014002 9.58 GFAP VIM
8 establishment of endothelial barrier GO:0061028 9.57 EZR MSN
9 establishment of epithelial cell apical/basal polarity GO:0045198 9.56 EZR MSN
10 positive regulation of myelination GO:0031643 9.55 S100B SOX10
11 positive regulation of cellular protein catabolic process GO:1903364 9.54 EZR MSN
12 positive regulation of phospholipase C activity GO:0010863 9.51 KIT PDGFRA
13 gland morphogenesis GO:0022612 9.49 EZR MSN
14 Bergmann glial cell differentiation GO:0060020 9.48 GFAP VIM
15 positive regulation of early endosome to late endosome transport GO:2000643 9.46 EZR MSN
16 regulation of cell shape GO:0008360 9.46 EZR KIT MSN S100B
17 positive regulation of protein localization to early endosome GO:1902966 9.4 EZR MSN
18 membrane to membrane docking GO:0022614 9.37 EZR MSN
19 regulation of organelle assembly GO:1902115 9.26 EZR MSN
20 intermediate filament-based process GO:0045103 8.96 GFAP VIM
21 intermediate filament organization GO:0045109 8.8 DES GFAP VIM

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.73 DES EZR GFAP S100B SOX10 VIM
2 S100 protein binding GO:0044548 9.37 EZR S100B
3 protein kinase A catalytic subunit binding GO:0034236 9.32 EZR PRKAR1A
4 structural constituent of cytoskeleton GO:0005200 9.26 DES GFAP MSN VIM
5 cytoskeletal protein binding GO:0008092 8.92 DES EZR MSN NF2
6 protein binding GO:0005515 10.03 DES ENO2 EZR GFAP KIT MSN
Sources

Sources for Neurilemmoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....